Biotech Drug Report Generated Sep 12, 2026

ANB033

TRAX·First Tracks Biotherapeutics, Inc.

BULLISH

Drug Impact Rating7/10

Trial Phase: Phase 1b
Time to Market: At least 3-5 years, assuming successful Phase 1b results, followed by larger Phase 2/3 trials and FDA review.
Why 7/10: The next hard, dated catalyst is the Cohort 1 Phase 1b data readout for ANB033 in celiac disease, expected in Q4 2026 (within ~3 months). ANB033 is the lead asset at First Tracks, which was spun off specifically to develop this pipeline, and the stock is described as a binary event-driven play on clinical data readouts. However, the company also has other programs (rosnilimab, ANB101), so it is not a pure single-asset binary, justifying a 7 rather than 8+.

Actionable Insight ▲ BULLISH

The next major catalyst is the Cohort 1 Phase 1b data readout for ANB033 in celiac disease, expected in Q4 2026. This is a binary event that will determine whether the drug shows proof-of-concept efficacy. With a Strong Buy consensus and mean price target of $69.44 (78% upside), the stock could move significantly on positive data. However, Phase 1b failure would likely erase a substantial portion of the company's value given ANB033 is the lead asset.

Price Chart

Loading chart...

Executive Summary

ANB033 is a clinical-stage antibody therapeutic being developed by First Tracks Biotherapeutics (Nasdaq: TRAX) for celiac disease, with an additional program in eosinophilic esophagitis. The company was spun off from AnaptysBio in April 2026 with $100M in cash and a $180M total cash position at launch. ANB033 is the lead pipeline asset and has received FDA Fast Track designation for celiac disease. The next major catalyst is Cohort 1 Phase 1b data readout expected in Q4 2026 (within ~3 months). The company has $168M in cash (as of June 30, 2026) with runway into Q2 2028. Analyst consensus is Strong Buy with a mean price target of $69.44, implying ~78% upside from the current ~$36.44 price. The stock is a binary event-driven play on the Phase 1b data.

How It Works

ANB033 is an antibody therapeutic designed to modulate immune pathways involved in autoimmune and inflammatory diseases. For celiac disease, it targets the immune response triggered by gluten ingestion, aiming to dampen the inflammatory attack on the small intestine without requiring patients to strictly avoid gluten.

Trial Status

ANB033 is currently in a Phase 1b clinical trial for celiac disease. The trial has two cohorts: Cohort 1 data is expected in Q4 2026, and Cohort 2 data is expected in Q1 2027. The FDA granted Fast Track designation for ANB033 in celiac disease as of Q2 2026. A separate program in eosinophilic esophagitis is expected to yield data in mid-2027.

The Two-Sided Case

▲ Bull Case5

FDA Fast Track designation for ANB033 in celiac disease de-risks the regulatory pathway and provides more frequent FDA interactions

Strong institutional backing with major holders including FMR LLC ($41.3M), BlackRock ($39.5M), Vanguard ($29.2M), and hedge funds like Point72 ($8.2M), Citadel ($3.4M), and D.E. Shaw ($2.6M)

Analyst consensus is Strong Buy (13 buy/strong buy vs 1 hold, 0 sell) with a mean price target of $69.44 — ~78% upside from the current ~$36.44 price

Cash runway into Q2 2028 ($168M as of June 30, 2026) provides ample funding through multiple data readouts without near-term dilution risk

Celiac disease affects ~1% of the global population and has limited treatment options — a successful therapy could address a large unmet need

▼ Bear Case5

ANB033 is still in early-stage Phase 1b testing — the vast majority of Phase 1/2 drugs fail to reach approval, making the Q4 2026 readout a high-risk binary event

The stock is described as a 'binary event-driven play on clinical data readouts' — a negative Phase 1b result could wipe out a substantial portion of the company's ~$1.6B market cap

The company has no approved products or revenue, meaning it relies entirely on capital markets and pipeline success for survival

A clinical hold was recorded on ANB033 as of March 31, 2026 (though it appears to have been resolved given the Fast Track designation and ongoing enrollment)

The S-1 resale registration for up to 10.5M shares from the March 2026 private placement creates potential overhang as those shares become freely tradable

Upcoming Catalysts

Cohort 1 Phase 1b data readout for ANB033 in celiac disease — Q4 2026
Cohort 2 Phase 1b data readout for ANB033 in celiac disease — Q1 2027
Phase 1b data for ANB033 in eosinophilic esophagitis — mid-2027

Source Filing

The SecBot filing or press-release report that triggered this drug report:

First Tracks Biotherapeutics, Inc. 8-K TRAX ·Originating report

Sources · 5

Hover a chip for the title

1 sec.gov2 sec.gov3 sec.gov4 sec.gov5 sec.gov